Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

Prof. C. Polman MD PhD; L. Kappos; M. S. Freedman; G. Edan; H.-P. Hartung; D. H. Miller; X. Montalbán; F. Barkhof; K. Selmaj; B. M. J. Uitdehaag; S. Dahms; L. Bauer; C. Pohl; R. Sandbrink

首页> 外文期刊>Journal of Neurology >Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

【24h】

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

机译：BENEFIT研究的亚组：发生MS的风险和干扰素β-1b的治疗效果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and ≥ 2 clinically silent brain MRI lesions.

机译：BENEFIT研究检查了临床孤立综合征（CIS）和≥2个临床无声脑MRI病变患者的干扰素β（IFNB）-1b治疗。

著录项

来源
《Journal of Neurology》 |2008年第4期|480-487|共8页
作者
Prof. C. Polman MD PhD; L. Kappos; M. S. Freedman; G. Edan; H.-P. Hartung; D. H. Miller; X. Montalbán; F. Barkhof; K. Selmaj; B. M. J. Uitdehaag; S. Dahms; L. Bauer; C. Pohl; R. Sandbrink;
展开▼
作者单位

Vrije Universiteit Medical Centre Amsterdam The Netherlands;

University Hospital Basel Switzerland;

The Ottawa Hospital Ottawa Canada;

Centre Hospitalier Universitaire Rennes France;

Heinrich-Heine-Universität Düsseldorf Germany;

Institute of Neurology University College London UK;

Hospital Vall d’Hebron Barcelona Spain;

Vrije Universiteit Medical Centre Amsterdam The Netherlands;

Medical Academy Lodz Poland;

Vrije Universiteit Medical Centre Amsterdam The Netherlands;

Bayer Schering Pharma AG Berlin Germany;

Bayer Schering Pharma AG Berlin Germany;

Bayer Schering Pharma AG Berlin Germany;

Bayer Schering Pharma AG Berlin Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
multiple sclerosis; CIS; MRI;

机译：多发性硬化;CIS;MRI;

相似文献

外文文献
中文文献
专利

1. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. [J] . Polman C, Kappos L, Freedman MS, Journal of neurology . 2008,第4期

机译：BENEFIT研究的亚组：发生MS的风险和干扰素β-1b的治疗效果。
2. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS (see comments) [J] . The Lancet . 1998,第9139期

机译：安慰剂对照多中心干扰素β-1b治疗继发性进行性多发性硬化症的随机试验。欧洲研究小组关于继发性进行性MS中干扰素β-1b的研究（请参阅评论）
3. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. [J] . Kappos L, Freedman MS, Polman CH, The Lancet . 2007,第9585期

机译：首次临床事件提示多发性硬化后，早期干扰素与延迟干扰素β-1b治疗对残疾的影响：BENEFIT研究的3年随访分析。
4. LC-MS/MS-BASED CHARACTERIZATION OF GLIOBLASTOMA CELL RESPONSES TO TYPE I INTERFERONS FOR ESTABLISHING DEFECTS IN ANTIVIRAL MECHANISMS [C] . Irina Tarasova, Alesya Tereshkova, Elizaveta Solovyeva, International Mass Spectrometry Conference . 2018

机译：基于LC-MS / MS的胶质母细胞瘤细胞对I型干扰素的表征，用于在抗病毒机制中建立缺陷
5. Interferons and dermal fibrotic disorders: Nitric oxide production and transforming growth factor-beta1 gene expression by normal and hypertrophic dermal fibroblasts and tissues after interferon treatment. [D] . Wang, Rijian. 1998

机译：干扰素和皮肤纤维化疾病：干扰素治疗后，正常和肥厚性真皮成纤维细胞和组织产生一氧化氮和转化生长因子-β1基因表达。
6. Interferon beta-1b in treatment-naïve paediatric patients with relapsing–remitting multiple sclerosis: Two-year results from the BETAPAEDIC study [O] . Jutta Gärtner, Wolfgang Brück, Almuth Weddige, 2017

机译：初治复发型多发性硬化儿科患者的干扰素β-1b：BETAPAEDIC研究的两年结果
7. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b [O] . Polman Chris H, Kappos Ludwig, Freedman Mark S, 2008

机译：BENEFIT研究的亚组：发生MS的风险和干扰素β-1b的治疗效果
8. Study of Chlamydia trachomatis in Military Women; Prevalence, Risk Factors, and a Cost Benefit Analysis of Early Diagnosis and Treatment [R] . Gaydos, C. A. 1999

机译：军人妇女沙眼衣原体的研究;早期诊断和治疗的患病率，危险因素和成本效益分析

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

摘要

著录项

相似文献

相关主题

期刊订阅